FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2286550014> ?p ?o ?g. }

• W2286550014 endingPage "731" @default.
• W2286550014 startingPage "722" @default.
• W2286550014 abstract "PurposeTo assess the long-term quality of life (QoL) outcomes from a phase 3 trial comparing 2 modes of intensity modulated radiation therapy (IMRT): conventional IMRT (CIMRT) versus hypofractionated IMRT (HIMRT) in patients with localized prostate cancer.Methods and MaterialsBetween 2002 and 2006, 303 men with low-risk to high-risk prostate cancer were randomized to 76 Gy in 38 fractions (CIMRT) versus 70.2 Gy in 26 fractions (HIMRT). QoL was compared by use of the Expanded Prostate Cancer Index Composite (EPIC), the International Prostate Symptom Score (IPSS), and EuroQoL (EQ5D) questionnaires. The primary outcome of the QoL analysis was a minimum clinically important difference defined as a 0.5 standard deviation change from baseline for each respective QoL parameter. Treatment effects were evaluated with the use of logistic mixed effects regression models.ResultsA total of 286, 299, and 218 patients had baseline EPIC, IPSS, or EQ5D data available and were included in the analysis. Overall, there was no statistically significant difference between the 2 treatment arms in terms of EPIC, IPSS, or EQ5D scores over time, although there was a trend toward lower EPIC urinary incontinence scores in the HIMRT arm. More patients in the HIMRT arm had a lower EPIC urinary incontinence score relative to baseline versus patients in the CIMRT arm with long-term follow-up. On multivariable analysis, there was no association between radiation fractionation scheme and any QoL parameter. When other clinical factors were examined, lymph node radiation was associated with worse EPIC hormonal scores versus patients receiving no lymph node radiation. In general, QoL outcomes were generally stable over time, with the exception of EPIC hormonal and EQ5D scores.ConclusionsIn this randomized prospective study, there were stable QoL changes in patients receiving HIMRT or CIMRT. Our results add to the growing body of literature suggesting that HIMRT may be an acceptable treatment modality in clinically localized prostate cancer. To assess the long-term quality of life (QoL) outcomes from a phase 3 trial comparing 2 modes of intensity modulated radiation therapy (IMRT): conventional IMRT (CIMRT) versus hypofractionated IMRT (HIMRT) in patients with localized prostate cancer. Between 2002 and 2006, 303 men with low-risk to high-risk prostate cancer were randomized to 76 Gy in 38 fractions (CIMRT) versus 70.2 Gy in 26 fractions (HIMRT). QoL was compared by use of the Expanded Prostate Cancer Index Composite (EPIC), the International Prostate Symptom Score (IPSS), and EuroQoL (EQ5D) questionnaires. The primary outcome of the QoL analysis was a minimum clinically important difference defined as a 0.5 standard deviation change from baseline for each respective QoL parameter. Treatment effects were evaluated with the use of logistic mixed effects regression models. A total of 286, 299, and 218 patients had baseline EPIC, IPSS, or EQ5D data available and were included in the analysis. Overall, there was no statistically significant difference between the 2 treatment arms in terms of EPIC, IPSS, or EQ5D scores over time, although there was a trend toward lower EPIC urinary incontinence scores in the HIMRT arm. More patients in the HIMRT arm had a lower EPIC urinary incontinence score relative to baseline versus patients in the CIMRT arm with long-term follow-up. On multivariable analysis, there was no association between radiation fractionation scheme and any QoL parameter. When other clinical factors were examined, lymph node radiation was associated with worse EPIC hormonal scores versus patients receiving no lymph node radiation. In general, QoL outcomes were generally stable over time, with the exception of EPIC hormonal and EQ5D scores. In this randomized prospective study, there were stable QoL changes in patients receiving HIMRT or CIMRT. Our results add to the growing body of literature suggesting that HIMRT may be an acceptable treatment modality in clinically localized prostate cancer." @default.
• W2286550014 created "2016-06-24" @default.
• W2286550014 creator A5017770546 @default.
• W2286550014 creator A5025874222 @default.
• W2286550014 creator A5033372450 @default.
• W2286550014 creator A5037162298 @default.
• W2286550014 creator A5038015667 @default.
• W2286550014 creator A5038032242 @default.
• W2286550014 creator A5043554307 @default.
• W2286550014 creator A5049646055 @default.
• W2286550014 creator A5052761167 @default.
• W2286550014 creator A5057775605 @default.
• W2286550014 creator A5060104637 @default.
• W2286550014 creator A5063389942 @default.
• W2286550014 creator A5075320625 @default.
• W2286550014 creator A5081839864 @default.
• W2286550014 date "2017-03-01" @default.
• W2286550014 modified "2023-09-24" @default.
• W2286550014 title "Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer" @default.
• W2286550014 cites W1583848026 @default.
• W2286550014 cites W1977733462 @default.
• W2286550014 cites W1993681878 @default.
• W2286550014 cites W2014198657 @default.
• W2286550014 cites W2014239903 @default.
• W2286550014 cites W2021220421 @default.
• W2286550014 cites W2033942571 @default.
• W2286550014 cites W2039003059 @default.
• W2286550014 cites W2047728355 @default.
• W2286550014 cites W2054899405 @default.
• W2286550014 cites W2071365490 @default.
• W2286550014 cites W2097532477 @default.
• W2286550014 cites W2098733695 @default.
• W2286550014 cites W2101001966 @default.
• W2286550014 cites W2104631398 @default.
• W2286550014 cites W2111180711 @default.
• W2286550014 cites W2114423034 @default.
• W2286550014 cites W2118792538 @default.
• W2286550014 cites W2130514725 @default.
• W2286550014 cites W2137282952 @default.
• W2286550014 cites W2144574555 @default.
• W2286550014 cites W2152182740 @default.
• W2286550014 cites W2153836018 @default.
• W2286550014 cites W2160612556 @default.
• W2286550014 cites W2170552969 @default.
• W2286550014 cites W2188246217 @default.
• W2286550014 cites W2520448081 @default.
• W2286550014 cites W2993539218 @default.
• W2286550014 cites W4252775619 @default.
• W2286550014 doi "https://doi.org/10.1016/j.ijrobp.2016.12.034" @default.
• W2286550014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5331910" @default.
• W2286550014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28244407" @default.
• W2286550014 hasPublicationYear "2017" @default.
• W2286550014 type Work @default.
• W2286550014 sameAs 2286550014 @default.
• W2286550014 citedByCount "36" @default.
• W2286550014 countsByYear W22865500142016 @default.
• W2286550014 countsByYear W22865500142017 @default.
• W2286550014 countsByYear W22865500142018 @default.
• W2286550014 countsByYear W22865500142019 @default.
• W2286550014 countsByYear W22865500142020 @default.
• W2286550014 countsByYear W22865500142021 @default.
• W2286550014 countsByYear W22865500142022 @default.
• W2286550014 crossrefType "journal-article" @default.
• W2286550014 hasAuthorship W2286550014A5017770546 @default.
• W2286550014 hasAuthorship W2286550014A5025874222 @default.
• W2286550014 hasAuthorship W2286550014A5033372450 @default.
• W2286550014 hasAuthorship W2286550014A5037162298 @default.
• W2286550014 hasAuthorship W2286550014A5038015667 @default.
• W2286550014 hasAuthorship W2286550014A5038032242 @default.
• W2286550014 hasAuthorship W2286550014A5043554307 @default.
• W2286550014 hasAuthorship W2286550014A5049646055 @default.
• W2286550014 hasAuthorship W2286550014A5052761167 @default.
• W2286550014 hasAuthorship W2286550014A5057775605 @default.
• W2286550014 hasAuthorship W2286550014A5060104637 @default.
• W2286550014 hasAuthorship W2286550014A5063389942 @default.
• W2286550014 hasAuthorship W2286550014A5075320625 @default.
• W2286550014 hasAuthorship W2286550014A5081839864 @default.
• W2286550014 hasBestOaLocation W22865500141 @default.
• W2286550014 hasConcept C121608353 @default.
• W2286550014 hasConcept C126322002 @default.
• W2286550014 hasConcept C126894567 @default.
• W2286550014 hasConcept C143998085 @default.
• W2286550014 hasConcept C159110408 @default.
• W2286550014 hasConcept C168563851 @default.
• W2286550014 hasConcept C188816634 @default.
• W2286550014 hasConcept C203092338 @default.
• W2286550014 hasConcept C2776235491 @default.
• W2286550014 hasConcept C2776547966 @default.
• W2286550014 hasConcept C2778531004 @default.
• W2286550014 hasConcept C2779478474 @default.
• W2286550014 hasConcept C2779951463 @default.
• W2286550014 hasConcept C2780192828 @default.
• W2286550014 hasConcept C509974204 @default.
• W2286550014 hasConcept C71924100 @default.
• W2286550014 hasConceptScore W2286550014C121608353 @default.
• W2286550014 hasConceptScore W2286550014C126322002 @default.
• W2286550014 hasConceptScore W2286550014C126894567 @default.
• W2286550014 hasConceptScore W2286550014C143998085 @default.

• next